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Background: Dementia, including Alzheimer’s disease (AD), is one of the most burdensome medical conditions. In
order to better understand the epidemiology of dementia in Italy, we conducted a systematic search of studies
published between 1980 and April 2014 investigating the prevalence of dementia and AD in Italy and then
evaluated the quality of the selected studies.
Methods: A systematic search was performed using PubMed/Medline and Embase to identify Italian population-based
studies on the prevalence of dementia among people aged ≥60 years. The quality of the studies was scored according
to Alzheimer’s Disease International (ADI) criteria.
Results: Sixteen articles on the prevalence of dementia and AD in Italy were eligible and 75 % of them
were published before the year 2000. Only one study was a national survey, whereas most of the studies
were locally based (Northern Italy and Tuscany). Overall, the 16 studies were attributed a mean ADI quality
score of 7.6 (median 7.75).
Conclusions: Available studies on the prevalence of dementia and AD in Italy are generally old, of weak
quality, and do not include all regions of Italy. The important limitations of the few eligible studies
included in our analysis, mostly related to their heterogeneous design, make our systematic review
difficult to interpret from an epidemiologic point of view. Full implementation of a Dementia National
Plan is highly needed to better understand the epidemiology of the disease and monitor dementia
patients.
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Rationale
Dementia, including Alzheimer’s disease (AD), is one of
the most burdensome medical conditions. As the preva-
lence of dementia increases with age, the number of
people living with this condition is expected to surge in
the next few decades as people live longer.
What is known about the epidemiology of dementia in
Italy comes from prevalence data which typically have
been generated from studies that may be inconsistent* Correspondence: mancini_michele@lilly.com
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(http://creativecommons.org/publicdomain/zeregarding diagnostic criteria, age of the studied popula-
tion, or assessments used [1–3]. While there are also
many publications on the prevalence of dementia in
Western European countries, the results of these studies
vary considerably [4]. There is therefore an urgent need
to come to a methodological consensus on how best to
design epidemiological studies of dementia [2].
One important determinant of a reliable evaluation
is the quality of the studies examined. In general, the
quality of prevalence studies of dementia to date re-
flects the difficulty of diagnosing dementia. It has
been suggested that a dementia diagnosis should be
based upon a multidomain cognitive test battery, an
informant interview, and a structured disabilityle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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other causes of cognitive impairment [4]. Following
very restricted criteria, Prince and colleagues [4] se-
lected and ranked 51 European studies according to
the standardized scoring system described in the 2009
Alzheimer Disease International (ADI) report [5]
(Appendix). In this very comprehensive work, the
European studies yielded a good (± standard devi-
ation) mean quality score, with 8.2 ± 1.8 points (range
of mean ± standard deviation quality scores of the
studies across all regions: 5 ± 0.7 to 9.7 ± 2; overall
mean all-region quality score: 7.9 ± 2) although only
8 % of the studies referred to post-2000 research.
This suggests that data are lacking on the prevalence
of dementia in Europe in the last decade [4]. Never-
theless, the authors confirmed the prevalence data re-
ported by the European Collaboration for Dementia
Group (EuroCoDe) [1], with an age and gender stan-
dardized prevalence of 7.3 %, which is very similar to
the 7.1 % prevalence previously estimated by the
EuroCoDe group [1].
Another important systematic review was con-
ducted on prevalence data of dementia in Europe by
the Alzheimer Cooperative Valuation in Europe
(ALCOVE) [6]. This systematic review took into con-
sideration both the quality of the studies (according
to the quality score proposed by the 2009 ADI re-
port [5]; Appendix) and the use of standardized clin-
ical criteria (e.g. Diagnostic and Statistical Manual of
Mental Disorders, DSM) [5, 7]. According to these
methods, only 3 of the 17 studies selected in the
EuroCoDe review [1] and 10 of the 12 studies in the
ALCOVE review [6] adopted the clinical criteria of
the DSM-IV. The DSM-IV criteria were chosen as a
benchmark by the authors because it was the most
frequently used method in these epidemiological
studies. The mean quality score of all studies that
adopted the DSM-IV criteria was 6.85 ± 1.93 (median
7, range 4.5–10.5), whilst in those with a quality
score ≥7 the authors found a prevalence of dementia
of 7.2 %. The use of these stringent criteria led to a
mean decrease of 22 % in total rate for dementia,
compared with the EuroCoDe review estimates [1],
and to a mean decrease of 12 % in the total rate of
dementia, compared with ALCOVE review estimates
[6].
Objectives
The objectives of this systematic review were: (i) to
conduct a review of studies on prevalence of demen-
tia in Italy; and (ii) to evaluate the quality of identi-
fied studies according to the standardized scoring
system for the assessment of epidemiological trials in
dementia.Methods
We estimated the quality of studies conducted on the
prevalence of dementia and AD in Italy by carrying out
a systematic review of the Italian literature published
between January 1st 1980 and April 1st 2014, using
PubMed/Medline and Embase and searching for the
following terms (in any field): (dementia OR
Alzheimer disease OR Alzheimer’s disease) AND
prevalence AND Italy, with no language restriction.
We sought and included all Italian population-based
studies on the prevalence of dementia among people
with age equal to or greater than 60 years old. In
order to get a comprehensive ranking of the quality
of studies published to date on the prevalence of
dementia and AD in Italy, we excluded only the
following papers:
1) Studies of prevalence from the follow-up phase of a
population cohort;
2) Studies of nursing home or residential care
populations, primary care attendees, or other
unrepresentative service-user populations;
3) Studies in which the ascertainment of dementia
depended upon help-seeking and/or receipt of
dementia care services;
4) Studies restricted to young-onset dementia:
5) Reviews, meta-analyses and pooled analyses were
not considered but could only have been used to
find the proper original studies.
Two authors read the abstracts of all publications
identified on the electronic databases, excluding only
those that clearly did not meet the aforementioned
eligibility criteria. In the next stage, four authors read
the full-text versions of the selected publications and
a consensus was reached regarding those remaining
studies which met all criteria. The process of article
selection followed PRISMA guidelines [8] and is illus-
trated in Fig. 1.
For evaluating the quality of the studies, we
adopted the same approach described in the review
by Prince et al. [4]. The scoring system used to assess
the quality of the studies (which considered sample
size, design, response proportion and diagnostic
assessment; range 0–11) is presented in Appendix. In
order to quantify the studies that adopted the DSM-
IV and the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzhei-
mer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria, the type of diagnostic
tool and clinical criteria for the diagnosis of dementia
were also considered [6]. When it was not clear how to
classify the quality of some publications, the four authors
came to a consensus following discussion. Zero points
Fig. 1 Overview of article selection (PRISMA 2009)
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plicable due to lack of information. In order to globally
evaluate the quality of the epidemiological data available
regarding the prevalence of dementia and AD in Italy, we
first scored each study and then calculated the mean,
range of scores, standard deviation and median of the
overall quality score.
Results
Our systematic search yielded titles for 977 publications
in Medline and for 966 publications in Embase. After
reading the abstracts, 954 publications from Medline
and 936 from Embase were excluded as clearly ineligible,
leaving 30 articles for further review. Of these 30 arti-
cles, 23 were common to both libraries and seven were
retrieved from Embase only. After obtaining copies of
the fully published versions of each study, 15 publica-
tions were excluded (including all seven additionalreferences from Embase) because they were deemed in-
eligible or were duplicates of publications already
included.
We therefore analyzed 15 publications [9–23],
comprising 14 different single studies and a pooled
data analysis of 4 studies [23]. Two out of the four
studies [10, 18] considered in the pooled data ana-
lysis [23] were already included in the list of the 14
single studies. Further to this, two other studies [24,
25] mentioned in the pooled analysis were also
added into our analysis. These two studies did not
focus on the prevalence of dementia and were not
identified using the keywords used for our literature
search; however, they did report data of interest. For
these last two studies we integrated the data of
interest obtained from the pooled analysis in
Francesconi et al. [23] with those in the original
publications. In this way, 16 of the 17 retrieved
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analysis [23], were included for the final analysis of
the quality score (Fig. 1). Features of each study
together with their quality score are outlined in
Table 1. Finally, as shown in Table 2, only the studies
included in the most comprehensive and frequently
cited European publications on the prevalence of
dementia in Europe were considered suitable for the
quality analysis [1, 4, 6, 26, 27]. Out of 16 selected
studies, 75 % (12 of 16) were published before the
year 2000. The mean gap between the year of survey
and year of publication was 4.1 ± 1.9 years (median,
4 years).
Apart from the Italian Longitudinal Study on Aging
(ILSA) survey [10], most of the studies evaluated the
prevalence of dementia in Northern Italy and Tuscany
(10 of 16). Two studies were conducted in Central
Italy [9, 11] and the remaining three studies were
performed in Sicily [15, 16, 21] (Fig. 2). Even
including the ILSA study, we did not find any data
on the prevalence of dementia for 10 out of 20 Italian
regions.
The prevalence of dementia in the Italian studies
ranged from a minimum of 5.9 % (for a sample
with range of 65–97 years) to a maximum of
61.9 % (for a sample with age >100 years) (Table 1).
Out of the 16 studies included in this review, 13
reported prevalence by age and sex. Ten of 16 ana-
lyzed studies (62.5 %) reported the specific preva-
lence data for AD. We found in these 10 studies
that the prevalence of AD increased with the age of
the studied population (from 3 % for a range of age
of 65–97 years old to 48.9 % for a study sample
with age >100 years old) (Table 1). Only the ILSA
study [10] had a sample size >3000 (Table 1).
Twenty-five percent of the studies (4 of 16) consid-
ered 60 years to be the minimum age for inclusion
(i.e. the conventional age threshold to define
elderly), while the majority of studies used 65 years
as the age threshold.
The majority of studies (62.5 %; 10 of 16) re-
ported a response rate greater than or equal to
80 %. Regarding study design, only three studies
(18 %) were performed with a one-phase design
method [13, 19, 20]. Of the remaining studies, 13
had a two-phase design and 10 were conducted
with sampling of screen negatives. No studies
adopted the weighting back method (for all
information see Table 1).
Table 1 also indicates the diagnostic tools used in
the 16 studies. With regard to diagnostic assessment,
the informant interview was performed in three of
the 16 studies. A total of six studies adopted the
NINCDS-ADRDA criteria, four studies adopted boththe NINCDS-ADRDA and the DSM-IV criteria, and
one study was performed with DSM-IV alone. The
assessment tool used was not reported in one of the
remaining five studies, whilst in four studies neither
the DSM-IV nor the NINCDS-ADRDA criteria were
utilized. Overall, the 16 epidemiological studies
scored a mean ADI quality score of 7.6 ± 1.4 with a
median of 7.75. As shown in Fig. 3, there was only a
slight tendency for study quality to improve over
time. When only the studies included in the Prince
et al. [4] analysis were considered, the mean quality
score of the Italian studies was found to be numeric-
ally less than that of the European studies (7.4 ± 1.1
vs. 8.2 ± 1.8) (Table 2).
Discussion
Summary of evidence
Overall, this systematic review showed that the
analyzed studies do not represent a valid source of
epidemiological data on the prevalence of dementia
in Italy. We found that, until now, no epi-
demiological data for 10 out of 20 Italian regions
were available and that the majority of epidemio-
logical studies were performed at the level of muni-
cipalities, with most studies conducted in Northern
Italy. Some regions were more affected by dementia
than others.
Irrespective of geographical distribution, the preva-
lence rates of dementia reported in the Italian stud-
ies vary widely which may be due to important
differences in methodological approaches and popu-
lation age ranges. In the 16 studies analyzed, we
found five different age ranges of study samples, a
discrepancy that makes it difficult to compare the
results of these studies and suggests a lack of meth-
odological consensus. Furthermore, it is important to
note that the only nationwide survey on the preva-
lence of dementia in Italy with a sample size >3000
subjects excluded those who were older than
84 years, an age range associated with a high rate of
dementia.
From a diagnostic methodological perspective, the
majority of Italian studies on the prevalence of
dementia and AD included in our analysis adopted
a two-phase design, but not all of them used sam-
pling of screen negatives and none of them adopted
the weighting back method. Furthermore, the in-
formant interview was performed in only a minority
of selected publications.
Overall, the Italian studies included in this review
had lower ADI quality scores than those of European
studies and, unlike the finding reported in the meta-
analysis of Prince et al. [4], quality showed only a
slight tendency to improve over time.
Table 1 Characteristics, scoring and prevalence of dementia/AD in studies carried out in Italy
First author and
year of publication
Year of
survey
Area of
investigation
Type of
dementia(s)
Age
(years)
Sample size
Score
Design
Score
Response
proportion
Score
Diagnostic
assessment
Score
Total
score
Prevalence
of dementia
Diagnostic
criteria tools
Rocca, 1990
[9]
1987 Appignano
(Macerata)
D (AD+MID
+MD)
>59 778
Score: 1
Two-phase design with
negative screen
Score: 1
96 %
Score: 3
AMT +MMSE+
Blessed-Roth+CE+IN
Score: 3
8 6.2 %
(2.6 % AD)
NINCDS-
ADRDA HIS
ILSA, 1997
[10]
1992–1993 8
municipalities
Any type 65–84 5632/5462
(total/
eligible)
Score: 2
Two-phase design with
negative screen
Score: 1
84-64 %a
Score: 3
IN + CE
(MMSE/ADL/IADL)
Score: 3
9 7.2 % F
5.3 % M
DSM-III-R
NINCDS-
ADRDA
ICD-10
Prencipe, 1996
[11]
1992–1993 Aquila
Province
D
(AD+VaD
+ODD)
>64 1147
Score: 1
Two-phase design with
negative screen
Score: 1
84.4 %
Score: 3
MMSE/MSQ + CE + IN +
disability assessment
Score: 4
9 8.0 %
(5.2 % AD)
NINCDS-
ADRDA
NINDS-AIREN
HIS
De Ronchi, 1998
[12]
1991 Granarolo
(Ravenna)
AD + VaD
+M
D
≥61 557
(481
completers)
Score: 1
Two-phase design with
no negative
Score: 0
86.4 %
Score: 3
MMSE/GDS + CE + IN +
ADL
Score: 2
6 11.1 % DSM III R
Benedetti, 2002
[13]
1996 Buttapietra
(Verona)
AD + VaD >74 238
Score: 0.5
One-phase design
Score: 2
93.3 %
Score: 3
MMSE + CE + IN + ADL
Score: 3
8.5 15.8 %
(6.7 % AD)
HIS
NINCDS-
ADRDA
DSM-III-R
Ferini-Strambi, 1997
[14]
1991 Vescovato
(Cremona)
AD + VaD
+MD + SeD
>59 856
(673
responders)
Score: 1
Two-phase design with
no negative
Score: 0
79 %
Score: 2
AMT + CE
Score: 2
5 9.8 %
(5.2 % AD)
NINCDS-ADRDA
NINDS-AIREN
D’Alessandro, 1996
[15]
1992 Troina
(Enna)
D (VaD) >74 365
Score: 0.5
Two-phase design with
negative screen
Score: 1
95 %
Score: 3
MMSE + CE + CDR
Score: 3
7.5 21.9 % DSM-III-R
HIS
Azzimondi, 1998
[16]
1992–1994 2 Sicilian
Communities
(data on S.
Agata Militello)
D (VaD) >74 408
Score: 1
Two-phase design with
negative screen
Score: 1
93 %
Score: 3
MMSE + CE + CDR
Score: 3
8 28.4 % DSM-III-RHIS
Cristina, 2001
[17]
1992–1993 Pavia Province D >65
(40 % 65–69
and all >70)
2442
Score: 1.5
Two-phase design with
negative sample
Score: 1
68 %
Score: 2
MMSE + IN + CE
Score: 3
7.5 11.8 % DSM-III-R
Tognoni, 2005
[18]
2000 Pisa Province
(Vecchiano)
VaD + AD+
LBD +MCI
>65 2366
Score: 1.5
Two-phase design with
indirect sample
of negative screen
68 %
Score: 2
MMSE/CDR/CAMDEX +
C E+ IN + ADL
Score: 3
7.5 6.2 %
(4.2 % AD)
NINCDS-
ADRDA
HIS
LBD
MCADRC DSM-IV
Lucca, 2011
[19]
2002–2010 Monzino
(Varese)
D (AD) ≥80
(80–100)
2316
Score: 1.5
One-phase design
Score: 2
88 %
Registered
Score: 3
MMSE/BIMC/CDR+CE +
IN+
disability assessment
Score: 4
10.5 32 % DSM-IV
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Table 1 Characteristics, scoring and prevalence of dementia/AD in studies carried out in Italy (Continued)
Ravaglia,1999
[20]
1994–1995 Bologna +
Ravenna
provinces
AD + VaD ≥100 154
Score: 0.5
One-phase design
Score: 2
65 %
Score: 2
MMSE + CE + IN+
disability assessment
Score: 3
7.5 61.9 %
(48.9 % AD)
DSM-IV
NINCDS-ADRDA
ICD 10
Spada, 2009
[21]
2005–2006 San Teodoro
(Enna)
AD + VaD
+ Others
60–85 374
Score: 0.5
Two-phase design with
no negative screen
sample
Score: 0
74.9 %
Score: 2
MMSE + CE + IN+
disability assessment
Score: 3
5.5 7.1 %
(4.1 % AD)
DSM IV
NINCDS-ADRDA
NINDS-AIREN
Ravaglia, 2002
[22]
1999–2000 Conselice
(Ravenna)
AD + VaD 65–97 1353
Score: 1
Two-phase design with
negative screen
sample
Score: 1
75 %
Score: 2
MMSE + CE + IN+
disability Assessment
Score: 3
7 5.9 %
(3.0 % AD)
DSM-IV
NINCDS-ADRDA
NINDS-AIREN
Ferrucci, 2000
[24]
1998 Greve in
Chianti + Bagno a
Ripoli (Florence)
D and AD >65–90+ 1260
Score: 1
Two-phase design with
negative screen
Score: 1
91.6 %b
Score: 3
MMSE + CE + IN+
disability assessment
Score: 3
8 7.1 % (3.6 %
AD)d
DSM-III-R
NINCDS-ADRDA
Di Bari, 1999
[25]
1995 Dicomano
(Florence)
D and AD >65–90+ 864
Score: 1
Two-phase design with
negative screen
Score: 0
91.2 %b
Score: 3
MMSEc + MODA + CE +
BADL
Score: 3
7 9.0 %
(5.2 % AD)d
Unknown
General: F females, M males, NA not available
Type of dementia and other diseases: AD Alzheimer Disease, D Dementia, LBD Lewy Body Dementia, MCI Mild Cognitive Impairment, MD Mixed Dementia, MID Multi-Infarct Dementia, ODD Other Dementing Diseases,
SeD Secondary Dementia, VaD Vascular Dementia
Area of investigation: SAM community of Sant’Agata Militello
Diagnostic assessment score: ADL Activities of Daily Living, AMT Abbreviated Mental Test, BADL Bristol Activities of Daily Living, BIMC Blessed Information Memory Concentration, CAMDEX Cambridge Mental Disorders of
the Elderly Examination, CDR Clinical Dementia Rating, CE Clinical Examination, GDS Global Deterioration Scale, IADL Instrumental Activities of Daily Living, IN Interview, MDS Minimum Data Set, MMSE Mini-Mental State
Examination, MODA Milan Overall Dementia Assessment, MSQ Mental Status Questionnaire
Diagnostic criteria tools: DSM Diagnostic and Statistical Manual of Mental Disorders, HIS Hachinski Ischemic Score, ICD International Classification of Diseases, MCADRC Mayo Clinic Alzheimer’s Disease Research Center,
NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association, NINDS-AIREN National Institute of Neurological Disorders and Stroke-
Association Internationale pour la Recherche et l’Enseignment en Neurosciences, RPM Raven Progressive Matrix
aResponse rates for personal interview and clinical evaluation, respectively
bCalculated on those who were traceable
cMMSE and adjustment tests when score falls between 22 and 25
dEstimated from Table 2 in the pooled analysis [23]
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Table 2 ADI quality score included in the meta-analysis on the prevalence of dementia in Europe (1980–2014)
First author and/or name of survey Range of time considered Italian studies included ADI quality score ADI quality score
(mean ± SD; median)
(mean ± SD; median)
Hofman, 1991, EURODEM [26] 1980–1990 Rocca et al., 1990 [9] 8 8
Lobo, 2000, EURODEM [27] 1990–2000 ILSA, 1997 [10] 9 9
Reynish, 2006, EUROCODE [1] 1990–2007 Prencipe et al., 1996 [11] 9 7.3 ± 1.5; 7.5
Ferini-Strambi et al., 1997 [14] 5
Azzimondi et al., 1998 [16] 8
Ravaglia et al., 2002 [22] 7
Tognoni et al., 2005 [18] 7.5
Galeotti, 2013, ALCOVE [6] 2007–2011 Lucca et al., 2011 [19] 10.5 10.5
Prince, 2013 [4] 1980–2009 Rocca et al., 1990 [9] 8 7.4 ± 1.1; 7.5
D’Alessandro et al., 1996 [15] 7.5
Prencipe et al., 1996 [11] 9
Ferini-Strambi et al., 1997 [14] 5
Azzimondi et al., 1998 [16] 8
De Ronchi et al., 1998 [12] 6
aDi Bari et al., 1999 [25] 8
Ravaglia et al., 1999 [20] 7.5
aFerrucci et al., 2000 [24] 8
Cristina et al., 2001 [17] 6.5
Ravaglia et al., 2002 [22] 7
Benedetti et al., 2002 [13] 8.5
Tognoni et al., 2005 [18] 7.5
ADI, Alzheimer Disease International, ALCOVE Alzheimer Cooperative Valuation in Europe, EuroCoDe European Collaboration for Dementia Group, ILSA Italian
Longitudinal Study on Aging
aFor the calculation of the ADI quality score, the items reported in these publications have been integrated with those reported in the pooled data of
Francesconi et al. [23]
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The finding of the lack of robust recent epidemio-
logical data is in accordance with the global data
reported in a meta-analysis, which showed that the
number of epidemiological studies on the prevalence
of dementia in high-income countries peaked in the
1990s and subsequently dropped off sharply [4].
Even if the prevalence of dementia and AD has not
changed significantly over time [1], the paucity of
epidemiological data on the prevalence of dementia
in Italy over the last ten years is regrettable and
has important implications from economic and so-
cial points of view. Indeed, annual updates of the
actual number of patients with dementia residing in
a country should be the first step in creating a pol-
icy supporting patients and their families. It is also
noteworthy that the geographic distribution of terri-
torial Alzheimer Evaluation Units in Italy is not
homogeneous, with the majority located in the
north of the country [28]. This geographicdistribution might explain, at least in part, why
most epidemiological studies on dementia and AD
in Italy have been performed in northern regions.
Another issue regarding studies on the prevalence
of age-related diseases like dementia and AD is the
timing of publication in relation to the time of
survey. At a national level, health policy strategy is
dependent on accurate and current estimates of the
size of the problem [1, 4]. The gap between the
dates of the surveys and their dates of publication,
together with the scarcity of recent data,
suggests that the available publications on the
prevalence of dementia in Italy may not represent
an up-to-date source of information for health eco-
nomic policy planning regarding patients with
dementia.
Epidemiological studies on prevalence of dementia
in Italy show low methodological quality. As Prince
et al. [4] reported, multiphase methods in general
tend to underestimate the prevalence of dementia and
Fig. 2 Geographic distribution and the relative number of Italian publications on prevalence of dementia (map created by authors). Note: The
asterisks refer to the municipalities included in the ILSA study [10]
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epidemiological studies [4], our analysis confirmed
that many studies omitted the informant interview.
Furthermore, prevalence estimates may reflect the
diagnostic criteria adopted by each study. For ex-
ample, a study that evaluated the prevalence of de-
mentia using different systems of classification found
that the proportion of subjects with dementia varied
from 3 % when International Classification of Dis-
eases (ICD)-10 criteria were used to 29 % when
DSM-III criteria were applied [7]. Similarly, the vari-
ability observed in European epidemiological studies
has been attributed precisely to the clinical criteriaadopted [1, 6]. In our analysis, 31 % of the studies
used neither the DSM-IV criteria nor the NINCDS-
ADRDA criteria. This finding represents a major
methodological issue considering that only the latter
diagnostic criteria have been validated with post-
mortem data [6].
The weak ADI quality scores of the Italian studies,
along with evidence that quality showed only a slight
tendency to improve over time, has important impli-
cations at the national healthcare system level. Since
no national survey commissioned by the Italian gov-
ernment has been performed in Italy, we suggest
that the Italian healthcare system should urgently
Fig. 3 Relationship between the quality of studies on the prevalence of dementia in Italy and the year of publication. ADI, Alzheimer Disease
International
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highest quality epidemiological methods, as defined
in the ADI 2009 report, and repeat them at regular
intervals to track any changes in the prevalence of
dementia or AD [4, 6].
Based on the findings of our systematic review, we
believe that the development of a national plan might be
an appropriate strategy to obtain epidemiological esti-
mates on dementia using the current healthcare system
and, at the same time, we encourage researchers to
undertake national surveys. A national plan might help
overcome differences between Italian regions, whilst the
detailed estimates obtained in this way might be useful
for policymaking, planning, and allocation of health and
welfare resources.Limitations
This review has several limitations First, our se-
lected studies included surveys that were not spe-
cifically dedicated to the prevalence of dementia
[10, 24, 25], which may have resulted in a bias in
the types of publications included in the review.
Second, although we reported that 75 % of studies
were published before the year 2000, this finding
might be due to our search methodology as
PubMed/Medline and Embase were the only data-
bases searched. However, this bias is unlikely to be
substantial since all studies included in our analysis
(Table 2) were also included in the most relevant
meta-analysis published in this field [4] Third, the
quality of studies included in this review was low.
Fourth, the mean gap of four years between theyear of survey and the year of publication should
also be taken into account. Fifth, the review was
not listed on an international prospective register of
systematic reviews such as PROSPERO [29]. Sixth,
this review has the intrinsic methodological
limitation that the prevalence rates derived from all
the analyzed studies have not been standardized or
compared with those of a reference population, e.g.
one chosen for age and sex. Finally, it should also
been taken into consideration that although the
quality of the studies only slightly improved over
time, our literature search for the studies on
prevalence began in 1980 and 75 % of the selected
studies were published prior to 2000. Therefore,
many of the included studies were unlikely to have
been conducted in conformity with current
requirements for epidemiological studies [30].Conclusions
Despite the availability of several publications, data on
the prevalence of dementia in Italy and their usefulness
for evaluating the epidemiological burden of the disease
in Italy are minimal. The majority of studies were con-
ducted in the 1990s with important methodological and
geographic differences that undermine determination of
the true national prevalence of dementia. Overall, the
quality of Italian studies was lower than that of
European studies and only slightly improved over time.
Full implementation of a Dementia National Plan would
help physicians, scientists and regulators to better
understand the epidemiology of dementia and AD in
Italy.
Bruti et al. BMC Health Services Research  (2016) 16:507 Page 10 of 11AppendixTable 3 Standardized scoring system for the assessment of quality of epidemiological trials in dementia [5]
Item Score
Sample size
<500 0.5 points
500–1499 1 point
1500–2999 1.5 points
≥3000 2 points
Design
Two-phase study with no sampling of screen negativesa 0 points
Two-phase study with sampling of screen negatives but no weighting back 1 point
One-phase study or two-phase study with appropriate sampling and weighting 2 points
Response proportion
<60 % 1 point
60–79 % 2 points
≥80 % 3 points
Diagnostic assessment
Inclusion of multidomain cognitive test battery, formal disability assessment, informant interview and clinical interview 1 point each
aIn the two-phase study, all participants are evaluated in the first phase using a screening tool. All the patients with a score below a predefined cutpoint (screen
positives) will enter into the second phase of the study for a more comprehensive evaluation. In order to get a more correct evaluation, a random sample with a
score above the cutpoint (screen negatives) should also be included in the second phase of the study. In this way the false positive rate can be estimated among
the screen negatives and the related weight (‘weight back’) can be evaluated, calculating an overall prevalence taking into account the different sampling
proportions of screen positives and screen negatives. In the one-phase study, all patients directly receive a comprehensive clinical evaluationAbbreviations
AD: Alzheimer Disease; ADI: Alzheimer Disease International;
ALCOVE: Alzheimer Cooperative Valuation in Europe; DSM: Diagnostic and
Statistical Manual of Mental Disorders; EuroCoDe: European Collaboration for
Dementia Group; ICD: International Classification of Diseases; ILSA: Italian
Longitudinal Study on Aging; NINCDS-ADRDA: National Institute of
Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease
and Related Disorders Association
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